A Rare Case of Ipilimumab-induced Reversible Hypophysitis and Permanent Primary Hypothyroidism
| Autor: | Mohanad Soliman, Amani Erra, Sabah Patel, Faisal Qureshi, Bibek Singh Pannu |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Oncology
medicine.medical_specialty Hypophysitis medicine.drug_class Permanent primary Ipilimumab 030204 cardiovascular system & hematology Monoclonal antibody 03 medical and health sciences 0302 clinical medicine Internal medicine Internal Medicine melanoma medicine ipilimumab Colitis Hepatitis business.industry Melanoma Thyroid Endocrinology/Diabetes/Metabolism General Engineering medicine.disease hypophysitis immune related adverse events medicine.anatomical_structure business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Cureus |
| ISSN: | 2168-8184 |
| DOI: | 10.7759/cureus.5001 |
| Popis: | Ipilimumab is a monoclonal antibody targeting the cytotoxic T-lymphocyte antigen-4 receptor, which was originally approved for the treatment of metastatic melanoma. It is the first immune checkpoint inhibitor to enter clinical practice. Immune toxicity due to ipilimumab causing colitis, hepatitis, and dermatitis are well-described in literature. We report a case of hypophysitis resolving with corticosteroid treatment, following which the patient developed long-term primary thyroid impairment. This highlights the importance of vigilance for rarer immune-related toxicities as clinical utilization of ipilimumab becomes more widespread. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|